171 related articles for article (PubMed ID: 37173386)
1. RapaCaspase-9-based suicide gene applied to the safety of IL-1RAP CAR-T cells.
Bouquet L; Bôle-Richard E; Warda W; Neto Da Rocha M; Trad R; Nicod C; Haderbache R; Genin D; Ferrand C; Deschamps M
Gene Ther; 2023 Sep; 30(9):706-713. PubMed ID: 37173386
[TBL] [Abstract][Full Text] [Related]
2. Overcoming target epitope masking resistance that can occur on low-antigen-expresser AML blasts after IL-1RAP chimeric antigen receptor T cell therapy using the inducible caspase 9 suicide gene safety switch.
Warda W; Da Rocha MN; Trad R; Haderbache R; Salma Y; Bouquet L; Roussel X; Nicod C; Deschamps M; Ferrand C
Cancer Gene Ther; 2021 Dec; 28(12):1365-1375. PubMed ID: 33414517
[TBL] [Abstract][Full Text] [Related]
3. Chimeric antigen receptor T-cells targeting IL-1RAP: a promising new cellular immunotherapy to treat acute myeloid leukemia.
Trad R; Warda W; Alcazer V; Neto da Rocha M; Berceanu A; Nicod C; Haderbache R; Roussel X; Desbrosses Y; Daguindau E; Renosi F; Roumier C; Bouquet L; Biichle S; Guiot M; Seffar E; Caillot D; Depil S; Robinet E; Salma Y; Deconinck E; Deschamps M; Ferrand C
J Immunother Cancer; 2022 Jul; 10(7):. PubMed ID: 35803613
[TBL] [Abstract][Full Text] [Related]
4. CAR-T cells targeting IL-1RAP produced in a closed semiautomatic system are ready for the first phase I clinical investigation in humans.
Nicod C; da Rocha MN; Warda W; Roussel X; Haderbache R; Seffar E; Trad R; Bouquet L; Goncalves M; Bosdure L; Laude MC; Guiot M; Ferrand C; Deschamps M
Curr Res Transl Med; 2023; 71(2):103385. PubMed ID: 36773434
[TBL] [Abstract][Full Text] [Related]
5. [IL-1RAP as a candidate for CAR T-cells immunotherapy].
Neto Da Rocha M; Trad R; Warda W; Haderbache R; Bouquet L; Nicod C; Deschamps M; Ferrand C
Med Sci (Paris); 2019; 35(6-7):497-500. PubMed ID: 31274074
[No Abstract] [Full Text] [Related]
6. A Rapamycin-Activated Caspase 9-Based Suicide Gene.
Stavrou M; Philip B; Traynor-White C; Davis CG; Onuoha S; Cordoba S; Thomas S; Pule M
Mol Ther; 2018 May; 26(5):1266-1276. PubMed ID: 29661681
[TBL] [Abstract][Full Text] [Related]
7. Generation of Suicide Gene-Modified Chimeric Antigen Receptor-Redirected T-Cells for Cancer Immunotherapy.
Minagawa K; Al-Obaidi M; Di Stasi A
Methods Mol Biol; 2019; 1895():57-73. PubMed ID: 30539529
[TBL] [Abstract][Full Text] [Related]
8. In Vitro Pre-Clinical Validation of Suicide Gene Modified Anti-CD33 Redirected Chimeric Antigen Receptor T-Cells for Acute Myeloid Leukemia.
Minagawa K; Jamil MO; Al-Obaidi M; Pereboeva L; Salzman D; Erba HP; Lamb LS; Bhatia R; Mineishi S; Di Stasi A
PLoS One; 2016; 11(12):e0166891. PubMed ID: 27907031
[TBL] [Abstract][Full Text] [Related]
9. Inducible apoptosis as a safety switch for adoptive cell therapy.
Di Stasi A; Tey SK; Dotti G; Fujita Y; Kennedy-Nasser A; Martinez C; Straathof K; Liu E; Durett AG; Grilley B; Liu H; Cruz CR; Savoldo B; Gee AP; Schindler J; Krance RA; Heslop HE; Spencer DM; Rooney CM; Brenner MK
N Engl J Med; 2011 Nov; 365(18):1673-83. PubMed ID: 22047558
[TBL] [Abstract][Full Text] [Related]
10. Inclusion of the Inducible Caspase 9 Suicide Gene in CAR Construct Increases Safety of CAR.CD19 T Cell Therapy in B-Cell Malignancies.
Guercio M; Manni S; Boffa I; Caruso S; Di Cecca S; Sinibaldi M; Abbaszadeh Z; Camera A; Ciccone R; Polito VA; Ferrandino F; Reddel S; Catanoso ML; Bocceri E; Del Bufalo F; Algeri M; De Angelis B; Quintarelli C; Locatelli F
Front Immunol; 2021; 12():755639. PubMed ID: 34737753
[TBL] [Abstract][Full Text] [Related]
11. Improving the safety of T-Cell therapies using an inducible caspase-9 gene.
Zhou X; Brenner MK
Exp Hematol; 2016 Nov; 44(11):1013-1019. PubMed ID: 27473568
[TBL] [Abstract][Full Text] [Related]
12. Droplet digital PCR allows vector copy number assessment and monitoring of experimental CAR T cells in murine xenograft models or approved CD19 CAR T cell-treated patients.
Haderbache R; Warda W; Hervouet E; da Rocha MN; Trad R; Allain V; Nicod C; Thieblemeont C; Boissel N; Varlet P; Agha IY; Bouquet L; Guiot M; Venet F; Sujobert P; Roussel X; Rouzaire PO; Caillot D; Casasnovas O; Bories JC; Bachy E; Caillat-Zucman S; Deschamps M; Ferrand C
J Transl Med; 2021 Jun; 19(1):265. PubMed ID: 34154602
[TBL] [Abstract][Full Text] [Related]
13. CML Hematopoietic Stem Cells Expressing IL1RAP Can Be Targeted by Chimeric Antigen Receptor-Engineered T Cells.
Warda W; Larosa F; Neto Da Rocha M; Trad R; Deconinck E; Fajloun Z; Faure C; Caillot D; Moldovan M; Valmary-Degano S; Biichle S; Daguindau E; Garnache-Ottou F; Tabruyn S; Adotevi O; Deschamps M; Ferrand C
Cancer Res; 2019 Feb; 79(3):663-675. PubMed ID: 30514753
[TBL] [Abstract][Full Text] [Related]
14. Engineering CD19-specific T lymphocytes with interleukin-15 and a suicide gene to enhance their anti-lymphoma/leukemia effects and safety.
Hoyos V; Savoldo B; Quintarelli C; Mahendravada A; Zhang M; Vera J; Heslop HE; Rooney CM; Brenner MK; Dotti G
Leukemia; 2010 Jun; 24(6):1160-70. PubMed ID: 20428207
[TBL] [Abstract][Full Text] [Related]
15. Combining a CD20 chimeric antigen receptor and an inducible caspase 9 suicide switch to improve the efficacy and safety of T cell adoptive immunotherapy for lymphoma.
Budde LE; Berger C; Lin Y; Wang J; Lin X; Frayo SE; Brouns SA; Spencer DM; Till BG; Jensen MC; Riddell SR; Press OW
PLoS One; 2013; 8(12):e82742. PubMed ID: 24358223
[TBL] [Abstract][Full Text] [Related]
16. Development of CAR T Cells Expressing a Suicide Gene Plus a Chimeric Antigen Receptor Targeting Signaling Lymphocytic-Activation Molecule F7.
Amatya C; Pegues MA; Lam N; Vanasse D; Geldres C; Choi S; Hewitt SM; Feldman SA; Kochenderfer JN
Mol Ther; 2021 Feb; 29(2):702-717. PubMed ID: 33129371
[TBL] [Abstract][Full Text] [Related]
17. Novel CAR T therapy is a ray of hope in the treatment of seriously ill AML patients.
Marofi F; Rahman HS; Al-Obaidi ZMJ; Jalil AT; Abdelbasset WK; Suksatan W; Dorofeev AE; Shomali N; Chartrand MS; Pathak Y; Hassanzadeh A; Baradaran B; Ahmadi M; Saeedi H; Tahmasebi S; Jarahian M
Stem Cell Res Ther; 2021 Aug; 12(1):465. PubMed ID: 34412685
[TBL] [Abstract][Full Text] [Related]
18. Systematic preclinical evaluation of CD33-directed chimeric antigen receptor T cell immunotherapy for acute myeloid leukemia defines optimized construct design.
Qin H; Yang L; Chukinas JA; Shah N; Tarun S; Pouzolles M; Chien CD; Niswander LM; Welch AR; Taylor N; Tasian SK; Fry TJ
J Immunother Cancer; 2021 Sep; 9(9):. PubMed ID: 34531250
[TBL] [Abstract][Full Text] [Related]
19. Treatment of Acute Myeloid Leukemia with T Cells Expressing Chimeric Antigen Receptors Directed to C-type Lectin-like Molecule 1.
Tashiro H; Sauer T; Shum T; Parikh K; Mamonkin M; Omer B; Rouce RH; Lulla P; Rooney CM; Gottschalk S; Brenner MK
Mol Ther; 2017 Sep; 25(9):2202-2213. PubMed ID: 28676343
[TBL] [Abstract][Full Text] [Related]
20. Redirecting Specificity of T cells Using the Sleeping Beauty System to Express Chimeric Antigen Receptors by Mix-and-Matching of VL and VH Domains Targeting CD123+ Tumors.
Thokala R; Olivares S; Mi T; Maiti S; Deniger D; Huls H; Torikai H; Singh H; Champlin RE; Laskowski T; McNamara G; Cooper LJ
PLoS One; 2016; 11(8):e0159477. PubMed ID: 27548616
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]